发明名称 Heterodimeric proteins and methods for producing and purifying them
摘要 The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and other heterodimeric proteins comprising immunoglobulin-like hinge sequences. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided.
申请公布号 US9527926(B2) 申请公布日期 2016.12.27
申请号 US201113697683 申请日期 2011.05.13
申请人 RINAT NEUROSCIENCE CORP. 发明人 Ho Wei-Hsien;Pons Jaume;Rajpal Arvind;Strop Pavel
分类号 C07K16/46;C07K16/28;C07K16/30;A61K39/00 主分类号 C07K16/46
代理机构 代理人 Yeh Jenny J.;Martin Deborah A.
主权项 1. A heterodimeric protein comprising: a hinge region comprising a first immunoglobulin-like hinge polypeptide and a second immunoglobulin-like hinge polypeptide which interact together to form a dimeric hinge interface, wherein electrostatic interactions between one or more charged amino acids within the hinge interface favor interaction between the first and second hinge polypeptides over interaction between two first hinge polypeptides or two second hinge polypeptides, thereby promoting heterodimer formation over homodimer formation, wherein the hinge region is a human IgG2 hinge region, wherein the first hinge polypeptide comprises at least one amino acid modification relative to a wild-type IgG hinge region; wherein the wild-type amino acid in the first hinge polypeptide is replaced with an amino acid having an opposite charge to the corresponding amino acid in the second hinge polypeptide, wherein the amino acid modification in the hinge region is at a position selected from the group consisting of Cys223 and Glu225 as shown at FIG. 6A, and further comprising an immunoglobulin-like CH3 region comprising a first CH3 polypeptide fused to the first hinge polypeptide and a second CH3 polypeptide fused to the second hinge polypeptide, wherein the first CH3 polypeptide and the second CH3 polypeptide comprise at least one amino acid modification relative to a wild-type IgG2 CH3 region sequence at a position selected from the group consisting of Leu368 and Lys409 (EU numbering scheme) as shown at FIG. 10.
地址 South San Francisco CA US